TMCnet News
CRWENewswire Stock Highlights: AQNM, PRWMAquentium Announces 475 Acre Algae BioFuel Production Project Aquentium, Inc., a publicly traded company in the United States of America (OTCBB: AQNM) announced today that the company has secured 475 acres in the State of New Mexico for the development of an algae bio-fuel production facility. Algae is uniquely suited to serve as the foundation for a new generation of renewable and low carbon transportation fuels. Algae is one of nature’s most prolific and efficient photosynthetic organisms. Nearly all of algae’s biomass is concentrated in the chloroplast, the engine that turns sunlight and CO2 into organic carbon, so that algae does not waste time or energy making stalks, roots, leaves, or fruits. This efficiency leads to very high yields of oil. About Aquentium Aquentium (OTCBB: AQNM) is a diversified publicly traded company with headquarters in the United States of America. The company and its subsidiaries have an emphasis on green technologies. The company currently has interests in alternative energy, waste-to-energy, non-chemical sanitation equipment, water treatment, food safety, mining, SIP building panels, low cost affordable housing, re-deployable housing structures, and recycling. Website: http://www.aquentium.com Tel: 951-657-8832 email: [email protected] THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Rule 17B requires disclosure of payment for investor relations. Aquentium is paying 100,000 restricted shares to Crown Equity Holdings for public relations services.. Sign up to receive FREE Stock-PR alerts from CRWENewswire.com at http://www.crwenewswire.com/?tag=stock-pr PWRM Interviewed by Wall Street Transcript Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced August 17, 2009 that the company’s CEO, Helen R. Park, M.S. was interviewed by the Wall Street Transcript, TWST, an on line magazine on Wednesday of last week. Ms. Park provided a company update on the state of the clinical trials for Neurodegenerative disease diagnostic tests and for breast cancer diagnostic tests. Specifically, she discussed the progress of the NuroPro® AD and NuroPro® PD clinical trials. Power3 has finished Phase I and reported the results at the International Congress of Alzheimer’s Disease (ICAD) in Vienna, Austria on July 14 2009. “This interview was a great opportunity to provide the newest information on not only our testing and but also the progress in our facing the economic situation”, commented Ms. Helen R. Park, CEO of Power3. “We were able to overcome this and recover from the damage done during hurricane IKE. This progress is thanks to our licensing agreement with Transgenomic, Inc. and the diligence of our staff at Power3. We are now moving to the Phase II, prospective samples for Alzheimer’s and Parkinson’s.” About Power3 Medical Products, Inc. Power3 Medical Products, Inc. (OTCBB:PWRM) (www.Power3Medical.com), is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio. Contact: Power3 Medical Products, Inc., Houston CEO Helen R. Park, M.S., 281-464-1600 Fax: 281-466-1481 [email protected] www.power3medical.com Forward Looking Statement This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for the completion of building a website for Power 3 Medical Products Inc. (PWRM.OB) About CRWENewswire.com CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc. CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above. We encourage investors to join and receive CRWENewswire.com FREE e-mail news and stock watch alerts at http://www.crwenewswire.com/?tag=stock-pr and view our full disclaimer. As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments. |